Allogeneic transplantation of hematopoietic cells is an effective treatment of leukemia, even
in advanced stages. Allogeneic lymphocytes produce a strong graft-versus-leukemia (GVL) …

Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin's lymphoma that
generally affects older individuals and continues to have one of the worst outcomes of all the …

T cells can be engineered to express the genes of chimeric antigen receptors (CARs) that
recognize tumor-associated antigens. We constructed and compared 2 CARs that contained …

Adoptive immunotherapy with T cells expressing a tumor-specific chimeric T-cell receptor is
a promising approach to cancer therapy that has not previously been explored for the …

Early results of the fludarabine, cyclophosphamide, and rituximab (FCR) regimen in 224
patients showed that it was highly active as initial therapy of chronic lymphocytic leukemia …

Purpose Evaluate response rate, duration of response (DOR), time-to-progression (TTP),
overall survival (OS), and safety of bortezomib treatment in patients with relapsed or …

To complement the existing treatment guidelines for all tumour types, ESMO organizes
consensus conferences to focus on specific issues in each type of tumour. In this setting, a …

Purpose Mantle cell lymphomas (MCLs) represent a clinically aggressive lymphoma
subtype with a poor prognosis. To explore a potential progress in outcome a historical …

Since allogeneic stem cell transplantation (SCT) represents an intensive curative treatment
for high-risk malignancies, its failure to prevent relapse leaves few options for successful …

Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative
disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell …